key: cord-0688641-dk2xastd
authors: Shah, Nishi; Dahi, Parastoo B.; Ponce, Doris M.; Sauter, Craig S.; Shaffer, Brian C.; Chung, David J.; Politikos, Ioannis; Lin, Richard J.; Giralt, Sergio A.; Papanicolaou, Genovefa; Ramanathan, Lakshmi V.; Perales, Miguel-Angel; Kamboj, Mini; Shah, Gunjan L.; Gyurkocza, Boglarka
title: HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION
date: 2021-10-11
journal: Transplant Cell Ther
DOI: 10.1016/j.jtct.2021.10.004
sha: 02ce7c7580dd19a44bc35f3014a9bdb873eb48bd
doc_id: 688641
cord_uid: dk2xastd

BACKGROUND: There are limited data on outcomes of patients with prior Coronavirus disease 2019 (COVID-19) who proceeded to autologous or allogeneic hematopoietic cell transplantation (HCT). It is unknown whether these patients are more susceptible to poor outcomes and recurrence of COVID-19. OBJECTIVE: We report a retrospective analysis of outcomes of 15 consecutive patients with hematologic malignancies who experienced COVID-19 and subsequently underwent autologous (n=8) or allogeneic (n=7) HCT between 6/17/20 and 2/17/21. The reported cohort included patients with asymptomatic past infections or symptomatic COVID-19 disease. METHODS: Data were obtained from chart review. Descriptive statistics were used to summarize patient characteristics. RESULTS: Among eight patients who underwent autologous HCT, four had a diagnosis of multiple myeloma while the rest had a diagnosis of non-Hodgkin's lymphoma. Four of the eight patients did not test positive for anti-SARS- CoV-2 IgG antibody at any point during their course. The remaining four patients had detectable anti-SARS-CoV-2 IgG antibodies prior to autologous HCT but only two of these patients remained anti-SARS-CoV-2 IgG antibody-positive at their last follow-up. One patient died from progression of disease. Seven patients with prior COVID-19 underwent allogeneic HCT for acute lymphoblastic leukemia (n=3); acute myeloid leukemia (n=1); chronic myeloid leukemia in lymphoid blast crisis (n=1); myelodysplastic syndrome (n=1); and myelofibrosis (n=1). Three of the seven patients tested positive for anti-SARS- CoV-2 IgG antibodies following the initial COVID-19 diagnosis; however, only one of these patients retained anti-SARS- CoV-2 IgG antibody following allogeneic stem cell transplantation. One patient died of infections (fungal and Pneumocystis jirovecii pneumonia) occurring in the context of ongoing treatment for GVHD. None of the 15 patients developed recurrence of COVID-19 infection. CONCLUSIONS: Based on our experience, autologous and allogeneic HCT can be safely performed in select patients with previous COVID-19 infection.

Seven patients with prior COVID-19 underwent allogeneic HCT for acute lymphoblastic leukemia (n=3); acute myeloid leukemia (n=1); chronic myeloid leukemia in lymphoid blast crisis (n=1); myelodysplastic syndrome (n=1); and myelofibrosis (n=1). Three of the seven patients tested positive for anti-SARS-CoV-2 IgG antibodies following the initial COVID-19 diagnosis; however, only one of these patients retained anti-SARS-CoV-2 IgG antibody following allogeneic stem cell transplantation. One patient died of infections (fungal and Pneumocystis jirovecii pneumonia) occurring in the context of ongoing treatment for GVHD.

None of the 15 patients developed recurrence of COVID-19 infection.

Conclusions: Based on our experience, autologous and allogeneic HCT can be safely performed in select patients with previous COVID-19 infection.

Patients with hematologic malignancies are at high risk for severe Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), due to immunocompromised state from their disease or treatment 1 .

There are limited data on outcomes of patients with prior COVID-19 who proceed to autologous or allogeneic hematopoietic cell transplantation (HCT) and specifically whether such patients are more susceptible to poor outcomes and recurrence of COVID-19 2,3 . Here we report a retrospective analysis of outcomes of 15 consecutive patients with hematologic malignancies who experienced COVID-19 and subsequently underwent autologous (n=8) or allogeneic (n=7) HCT during the COVID-19 pandemic.

Data on patients with hematologic malignancies who experienced COVID-19 and subsequently underwent HCT were obtained through retrospective chart review. Any patient with prior hematologic malignancy who was treated at MSKCC for their autologous or allogeneic HCT and had a prior COVID-19 infection was included in our study. The reported cohort included patients with asymptomatic past infections or symptomatic COVID-19 disease.

Standard eligibility criteria based on organ function and pre-transplant performance status were applied. These criteria have not changed substantially during the study period. Data regarding their demographics, disease characteristics, organ function, prior treatment information for COVID-19, clinical course peri-transplant and specific transplant related information were collected.

Relapse was defined as clinical, radiologic or biopsy proven evidence of disease after a period of remission from the disease.

The International Bone Marrow Transplant Registry classification was followed when grading acute GVHD, except grades A to D were labeled grades I to IV. Graft-versushost disease with purely acute features was graded accordingly, even if it occurred after day 100. 4 Grading was reviewed by a transplantation clinician panel to reach consensus of maximum grade of GVHD grade.

Routine surveillance testing for SARS-CoV-2 was not performed after admission for transplant. Symptom-based testing was performed with guidance from Infectious Disease experts. For anti-SARS-CoV-2 immunoglobulin G (IgG) antibody testing the Abbott Architect SARS-CoV-2 IgG assay (Abbott Park, IL, USA) was utilized, to detect serum immunoglobulin G (IgG) antibodies directed against the nucleocapsid protein of SARS-CoV-2 in routine clinical practice.

Descriptive statistics were used to summarize patient characteristics. Time from diagnosis of COVID-19 to HCT and from HCT to last follow-up was calculated for each patient and graphically charted.

Patients were in private rooms, per standard practice at our institution. All patients received supportive care and prophylaxis against opportunistic infections according to standard guidelines 5, 6 . Patients conditioned with busulfan received seizure prophylaxis with levetiracetam. All patients received cryopreserved peripheral blood stem cell (PBSC) grafts. Granulocyte colony-stimulating factor (G-CSF) was given beginning on day +7 post-transplant, until an absolute neutrophil count (ANC) of 2 x 10 9 /L was observed for three consecutive days.

Of these, 8 patients underwent autologous HCT and 7 patients underwent allogeneic HCT.

Patient demographics and transplant characteristics are summarized in Table 1 There are limited data on the pre-HCT COVID-19 course for two patients, as they were diagnosed and treated for COVID-19 at outside institutions. Six patients presented with symptoms prompting evaluation for COVID-19, with no data on one patient's presentation. Symptoms included fever, cough, sore throat, and shortness of breath.

Five patients required hospitalization for COVID-19, with one requiring supplemental O 2 by nasal cannula and one requiring ICU admission and mechanical ventilation.

Hospitalized patients were treated with azithromycin (n=2), hydroxychloroquine (n=1), remdesivir (n=1), methylprednisolone (n=1), anakinra on a clinical trial (n=1), and convalescent plasma (n=1).

Pre-transplant PFT showed DLCO, hemoglobin-adjusted of < 65% in one patient, between 66% and 80% in two patients and > 80% in four patients. Pre-transplant lung imaging showed nearly resolved previously seen patchy ground glass opacities (n=2), stable interstitial thickening and bronchiectasis when compared to previous studies Three of the seven patients tested positive for anti-SARS-CoV-2 IgG antibodies following the initial COVID-19 diagnosis; however, only one of these patients retained anti-SARS-CoV-2 IgG antibody on day +37 following allogeneic HCT (Figure 1 

Our study adds to growing body of knowledge regarding COVID-19 and its impact on clinical outcomes of a distinctly vulnerable clinical population of HCT recipients. We previously showed that the COVID-19 pandemic caused substantial delays in HCT and that these delays resulted in inferior outcomes in a select group of patients and that patients who developed COVID-19 after HCT had varied clinical outcomes [7] [8] [9] . In the current cohort of patients with previous COVID-19 infections autologous and allogeneic HCTs were feasible and safe; no recurrent COVID-19 infection was observed.

We also reported persistent COVID-19 infection in immunocompromised patients, highlighting the potential risk of proceeding to HCT 10 . Our current analysis supports proceeding with planned autologous or allogeneic HCT in patients who have recovered from COVID-19. Cohorting of patients beyond standard HCT algorithms or surveillance testing is not supported by our findings, as patients did not have reactivation or recurrence of COVID-19. The patients in this series developed COVID-19 infection early in the pandemic and their treatment reflects available therapies at that time. Given the low prevalence of SARS-CoV-2 in the community at the time of this study, routine surveillance testing for SARS-CoV-2 was not performed after admission for transplant.

Symptom-based testing was performed with guidance from Infectious Disease experts.

Limitations of the current study are its retrospective nature, small sample size, a relatively short follow-up period, and potentially a selection bias given that patients with more severe complications after COVID-19 infection were not considered appropriate HCT candidates. There may have also been a referral bias where patients who had significant complications from COVID-19 were not referred to the transplant program.

While patients in this dataset did well after HCT, the median time from COVID-19 diagnosis to HCT was long, and patients with recent SARS-CoV-2 infection in need of urgent HCT should be evaluated on a case by case basis to optimize outcomes. Table 1 .

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection

IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Realworld experience

Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

 Table 1 . Patient and transplant characteristics. The order of patients is the same as in Table S1 : Pre-transplant blood cell counts obtained on admission and ferritin levels (when assessed within 30 days pre-transplant). The order of patients is the same as in Figure 1 . and in Table 1 .